These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 36198786)

  • 1. Using proteins to test for COVID antibodies.
    Santoro H
    Nature; 2022 Oct; 610(7930):S3. PubMed ID: 36198786
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of antibody tests against SARS-CoV-2 for health care workers after vaccination.
    Kittanakom S; Richardson DC; Uddayasankar U; Knauer M; Borgia SM; Kavsak PA
    Clin Biochem; 2022 Mar; 101():54-55. PubMed ID: 34843731
    [No Abstract]   [Full Text] [Related]  

  • 3. Assay requirements for COVID-19 testing: serology vs. rapid antigen tests.
    Prassas I; Fiala C; Diamandis EP
    Clin Chem Lab Med; 2021 Aug; 59(9):e348-e350. PubMed ID: 33730769
    [No Abstract]   [Full Text] [Related]  

  • 4. Seroreactivity with COVID-19 antibody testing in CCP donors presenting without a SARS-CoV-2 diagnostic test.
    Goodhue Meyer EK; Xu M; Lasky B; Young PP
    Transfusion; 2021 Jan; 61(1):330-331. PubMed ID: 33037643
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of antibody tests for COVID-19 in primary care.
    Zarif A; McGagh D; Hoang U; de Lusignan S
    Br J Gen Pract; 2021; 71(704):131-134. PubMed ID: 33632693
    [No Abstract]   [Full Text] [Related]  

  • 6. A qualitative IgG ELISA for detection of SARS-CoV-2-specific antibodies in Syrian hamster serum samples.
    Shete A; Mohandas S; Jain R; Yadav PD
    STAR Protoc; 2021 Jun; 2(2):100573. PubMed ID: 33997801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SnapShot: SARS-CoV-2 antibodies.
    Montefiori DC; Acharya P
    Cell Host Microbe; 2021 Jul; 29(7):1162-1162.e1. PubMed ID: 34265246
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19.
    Vogelzang EH; Loeff FC; Derksen NIL; Kruithof S; Ooijevaar-de Heer P; van Mierlo G; Linty F; Mok JY; van Esch W; de Bruin S; Vlaar APJ; ; Seppen B; Leeuw M; van Oudheusden AJG; Buiting AGM; Jim KK; Vrielink H; Swaneveld F; Vidarsson G; van der Schoot CE; Wever PC; Li W; van Kuppeveld F; Murk JL; Bosch BJ; Wolbink GJ; Rispens T
    J Immunol; 2020 Dec; 205(12):3491-3499. PubMed ID: 33127820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.
    Zeng W; Ma H; Ding C; Yang Y; Sun Y; Huang X; He W; Xiang Y; Gao Y; Jin T
    Signal Transduct Target Ther; 2021 Jan; 6(1):35. PubMed ID: 33514692
    [No Abstract]   [Full Text] [Related]  

  • 10. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.
    Tang MS; Case JB; Franks CE; Chen RE; Anderson NW; Henderson JP; Diamond MS; Gronowski AM; Farnsworth CW
    Clin Chem; 2020 Dec; 66(12):1538-1547. PubMed ID: 32894750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical value of anti-SARS-COV-2 serum IgA titration in patients with COVID-19.
    Lippi G; Mattiuzzi C
    J Med Virol; 2021 Mar; 93(3):1210-1211. PubMed ID: 32966614
    [No Abstract]   [Full Text] [Related]  

  • 12. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19: Significance of antibodies.
    Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
    Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.
    Ahn TS; Han B; Krogstad P; Bun C; Kohn LA; Garcia-Lloret MI; Damoiseaux R; Butte MJ
    J Allergy Clin Immunol; 2021 Mar; 147(3):876-877. PubMed ID: 33358557
    [No Abstract]   [Full Text] [Related]  

  • 15. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice.
    Wang W; Huang B; Zhu Y; Tan W; Zhu M
    Cell Mol Immunol; 2021 Mar; 18(3):749-751. PubMed ID: 33580169
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles.
    Miyakawa K; Jeremiah SS; Ohtake N; Matsunaga S; Yamaoka Y; Nishi M; Morita T; Saji R; Nishii M; Kimura H; Hasegawa H; Takeuchi I; Ryo A
    J Mol Cell Biol; 2020 Nov; 12(12):987-990. PubMed ID: 32931563
    [No Abstract]   [Full Text] [Related]  

  • 17. Endemic SARS-CoV-2 will maintain post-pandemic immunity.
    Veldhoen M; Simas JP
    Nat Rev Immunol; 2021 Mar; 21(3):131-132. PubMed ID: 33402727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.
    Miyakawa K; Jeremiah SS; Kato H; Yamaoka Y; Go H; Yajima S; Shimada T; Mihara T; Goto A; Yamanaka T; Ryo A
    J Mol Cell Biol; 2022 Jan; 13(12):918-920. PubMed ID: 34450642
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19
    Yuen RR; Steiner D; Pihl RMF; Chavez E; Olson A; Smith EL; Baird LA; Korkmaz F; Urick P; Sagar M; Berrigan JL; Gummuluru S; Corley RB; Quillen K; Belkina AC; Mostoslavsky G; Rifkin IR; Kataria Y; Cappione AJ; Gao W; Lin NH; Bhadelia N; Snyder-Cappione JE
    Front Immunol; 2021; 12():614676. PubMed ID: 33897682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Meylan P
    Rev Med Suisse; 2021 Feb; 17(724):278. PubMed ID: 33538145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.